Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PROCEPT BioRobotics (PRCT) EBITDA (2020 - 2025)

PROCEPT BioRobotics has reported EBITDA over the past 6 years, most recently at -$29.8 million for Q4 2025.

  • Quarterly results put EBITDA at -$29.8 million for Q4 2025, down 59.42% from a year ago — trailing twelve months through Dec 2025 was -$95.6 million (down 4.67% YoY), and the annual figure for FY2025 was -$95.6 million, down 4.67%.
  • EBITDA for Q4 2025 was -$29.8 million at PROCEPT BioRobotics, down from -$21.2 million in the prior quarter.
  • Over the last five years, EBITDA for PRCT hit a ceiling of -$12.8 million in Q1 2021 and a floor of -$29.8 million in Q4 2025.
  • Median EBITDA over the past 5 years was -$21.8 million (2022), compared with a mean of -$22.0 million.
  • Biggest five-year swings in EBITDA: tumbled 65.64% in 2023 and later skyrocketed 31.7% in 2024.
  • PROCEPT BioRobotics' EBITDA stood at -$18.4 million in 2021, then crashed by 54.65% to -$28.4 million in 2022, then rose by 3.45% to -$27.4 million in 2023, then surged by 31.7% to -$18.7 million in 2024, then plummeted by 59.42% to -$29.8 million in 2025.
  • The last three reported values for EBITDA were -$29.8 million (Q4 2025), -$21.2 million (Q3 2025), and -$19.9 million (Q2 2025) per Business Quant data.